Anavex Life Sciences (AVXL) to Release Quarterly Earnings on Monday

Posted by Brian Himes on Aug 3rd, 2026

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.08) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. On average, analysts expect Anavex Life Sciences to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL traded up $0.12 during mid-day trading on Monday, reaching $2.87. The company had a trading volume of 490,499 shares, compared to its average volume of 1,332,717. Anavex Life Sciences has a twelve month low of $2.26 and a twelve month high of $11.70. The stock has a market capitalization of $265.50 million, a PE ratio of -7.29 and a beta of 1.15. The stock’s 50 day moving average is $2.61 and its 200-day moving average is $3.44.

Institutional Investors Weigh In On Anavex Life Sciences

A number of large investors have recently bought and sold shares of the business. State of Wyoming acquired a new position in Anavex Life Sciences during the second quarter worth $26,000. Quarry LP acquired a new stake in shares of Anavex Life Sciences in the third quarter worth about $36,000. Aigen Investment Management LP bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth about $44,000. Integrated Wealth Concepts LLC bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth about $46,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Anavex Life Sciences by 11,540.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 6,924 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings downgraded Anavex Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Rodman & Renshaw began coverage on Anavex Life Sciences in a research note on Monday, May 4th. They issued a “buy” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $21.33.

Get Our Latest Research Report on AVXL

About Anavex Life Sciences

(Get Free Report)

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.